Singapore, September 8, 2010: European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) meets today to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim.
Because of the complexity of the data being assessed, the committee is holding this additional meeting outside of its usual monthly schedule. This will allow the CHMP to prepare for its next scheduled meeting on September 20-23, 2010, when it expects to finalize the review of rosiglitazone.
The CHMP will also be taking the opportunity to discuss its ongoing investigation into whether there is a risk of narcolepsy with the influenza vaccine Pandemrix. After the meeting, the agency will make public the next steps agreed by the committee.
| 
Comment on this article
